Evercore Wealth Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Evercore Wealth Management’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-146,676	Closed	-$381K	–	432
2023 Q2	$381K	Hold	146,676	–	–	0.01%	303
2023 Q1	$267K	Hold	146,676	–	–	0.01%	346
2022 Q4	$242K	Hold	146,676	–	–	0.01%	356
2022 Q3	$282K	Hold	146,676	–	–	0.01%	323
2022 Q2	$439K	Hold	146,676	–	–	0.01%	276
2022 Q1	$553K	Buy	+146,676	New	+$835K	0.01%	268

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

VAS

VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Evercore Wealth Management's CYT Position: Q3 2023 in Review

Evercore Wealth Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2023, closing a stake of 146,676 shares — an estimated $381K sold.

Evercore Wealth Management first reported a position in CYT in Q1 2022 and held it in 6 quarters. The position peaked at $553K in Q1 2022. 41 funds tracked by Wall St. Rank hold CYT as of Q3 2023.

Evercore Wealth Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Evercore Wealth Management sold 146,676 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $381K.
Evercore Wealth Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Evercore Wealth Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $553K in Q1 2022.
41 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Evercore Wealth Management's 13F filing for Q3 2023, filed 14 Nov 2023.